Clinical Trials Logo
  1. Home
  2. Uterine Cervical Cancer
  3. NCT00266084
  4. Details
NCT00266084 Clinical Trial

Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix

Uterine Cervical Cancer Clinical Trial

Official title:
Double-Blinded Multicenter Clinical Study Assessing the Equivalence of the InPath Cervical Cell Collector to the Standard Endocervical Brush and Spatula in Patients Seeking Primary Pap Screening or Follow-up Screening

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00266084
Other study ID # 02-00-16
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received December 14, 2005
Last updated May 10, 2016
Start date August 1999
Est. completion date November 2001

Study information
Verified date November 2001
Source University Hospital Case Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This study tested the safety and performance of a new cell collector device and compared the results to those obtained with the current existing device that are being used routinely

Description:

This study tested the feasibility, safety and efficacy of the new e2TM Collector, and compared its performance with the standard method for obtaining cervical cells for Pap test of endocervical cytobrush and Ayer's Spatula

Recruitment information / eligibility
Status Completed
Enrollment 85
Est. completion date November 2001
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 14 Years and older
Eligibility Inclusion Criteria:

Women ages >14 being followed for a previous abnormal Pap All patients will have signed an Informed Consent form prior to being enrolled in this study

Exclusion Criteria:

Patients who have had a hysterectomy

Study Design

N/A

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
University Hospital Case Medical Center
See also
  Status Clinical Trial Phase
Terminated NCT01234480 - Intended Use Study of the BD SurePath Plus™ Pap
Completed NCT05022511 - Three Birds With One Stone N/A
Recruiting NCT04857528 - Detecting HPV DNA in Anal and Cervical Cancers
Completed NCT01755897 - A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients N/A
Recruiting NCT01667211 - Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer Phase 2
Active, not recruiting NCT01226264 - Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence N/A
Recruiting NCT03961191 - DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
Not yet recruiting NCT06254846 - Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study). N/A
Enrolling by invitation NCT01393470 - Evaluation of Long-term HPV Vaccine Efficacy N/A
Terminated NCT00421096 - Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer Phase 2
Terminated NCT01284348 - To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer Phase 2
Recruiting NCT03961178 - A Cohort Study for the Following up of Conization
Terminated NCT02317302 - FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer Phase 1
Not yet recruiting NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Phase 2
Completed NCT00184093 - Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma Phase 1/Phase 2
Recruiting NCT03960879 - DNA Methylation for Screening Uterine Cervical Lesions
Recruiting NCT04886700 - Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer Phase 2
Completed NCT02095119 - A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer Phase 1/Phase 2
Enrolling by invitation NCT05231993 - Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening N/A
Recruiting NCT02036164 - Adjuvant Chemotherapy for Locally Advanced Cervical Cancer Phase 3